Abstract
Lactoferrin is a secreted protein related to transferrin. Lactoferrin indirectly protects host cells against foreign insults by killing bacteria, scavenging free iron, and binding to receptors required for viral invasion. However, lactoferrin is also proposed to act directly on cells as a transcription factor and tumor suppressor gene. In addition to full length lactoferrin, a truncated form, called delta lactoferrin, can also be produced by alternative splicing. We show here that transformed and nontransformed cells are equally able to express both full length and delta lactoferrin. Moreover, both forms of lactoferrin failed to substantially modulate the expression of other genes. Thus, lactoferrin does not seem to directly control gene expression or inhibit tumor cell growth.
Keywords: lactoferrin, glycoprotein, expression, tumor, transcripts
Medicinal Chemistry
Title: Full Length and Delta Lactoferrin Display Differential Cell Localization Dynamics, but do not Act as Tumor Markers or Significantly Affect the Expression of Other Genes
Volume: 1 Issue: 1
Author(s): Gary S. Goldberg, Takehiko Kunimoto, David B. Alexander, Kayoko Suenaga, Fumiyoshi Ishidate, Kazuaki Miyamoto, Toshikazu Ushijima, Christina T. Teng, Jun Yokota, Tsutomu Ohta and Hiroyuki Tsuda
Affiliation:
Keywords: lactoferrin, glycoprotein, expression, tumor, transcripts
Abstract: Lactoferrin is a secreted protein related to transferrin. Lactoferrin indirectly protects host cells against foreign insults by killing bacteria, scavenging free iron, and binding to receptors required for viral invasion. However, lactoferrin is also proposed to act directly on cells as a transcription factor and tumor suppressor gene. In addition to full length lactoferrin, a truncated form, called delta lactoferrin, can also be produced by alternative splicing. We show here that transformed and nontransformed cells are equally able to express both full length and delta lactoferrin. Moreover, both forms of lactoferrin failed to substantially modulate the expression of other genes. Thus, lactoferrin does not seem to directly control gene expression or inhibit tumor cell growth.
Export Options
About this article
Cite this article as:
Goldberg S. Gary, Kunimoto Takehiko, Alexander B. David, Suenaga Kayoko, Ishidate Fumiyoshi, Miyamoto Kazuaki, Ushijima Toshikazu, Teng T. Christina, Yokota Jun, Ohta Tsutomu and Tsuda Hiroyuki, Full Length and Delta Lactoferrin Display Differential Cell Localization Dynamics, but do not Act as Tumor Markers or Significantly Affect the Expression of Other Genes, Medicinal Chemistry 2005; 1(1) . https://dx.doi.org/10.2174/1573406053402532
DOI https://dx.doi.org/10.2174/1573406053402532 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Non-squamous Tumors of the Oropharynx and Oral Cavity: CT and MR Imaging Findings with Clinical- Pathologic Correlation
Current Medical Imaging ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Inhibiting TLR9 Signaling Stimulates Apoptosis and Cell Cycle Arrest, and Alleviates Angiogenic Property in Human Cervical Cancer Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Current Approaches to Glycoprotein Analysis
Protein & Peptide Letters Prevalence and Distribution of Human Papillomavirus Genotype in South Eastern Italy, in the Period 2006-2011: Implications for Intervention
Current Pharmaceutical Design Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design